相似文献
1
Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae).
Antiviral Res. 2018 Jan;149:75-77. doi: 10.1016/j.antiviral.2017.11.011. Epub 2017 Nov 15.
2
Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02372-19.
3
Characterization of Pathogenesis and Inflammatory Responses to Experimental Parechovirus Encephalitis.
Front Immunol. 2021 Nov 25;12:753683. doi: 10.3389/fimmu.2021.753683. eCollection 2021.
4
Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
Antimicrob Agents Chemother. 2013 Oct;57(10):4841-7. doi: 10.1128/AAC.00850-13. Epub 2013 Jul 22.
5
Posaconazole inhibits dengue virus replication by targeting oxysterol-binding protein.
Antiviral Res. 2018 Sep;157:68-79. doi: 10.1016/j.antiviral.2018.06.017. Epub 2018 Jul 3.
6
In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
Med Mycol. 2005 Mar;43(2):179-85. doi: 10.1080/13693780410001731583.
7
Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3.
Antiviral Res. 2019 Feb;162:51-53. doi: 10.1016/j.antiviral.2018.12.009. Epub 2018 Dec 12.
8
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06.
9
Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.
Antivir Ther. 2011;16(4):611-4. doi: 10.3851/IMP1792.
10
Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01480-16. Print 2017 Mar.
引用本文的文献
1
Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases.
BMC Med. 2022 Oct 21;20(1):359. doi: 10.1186/s12916-022-02558-z.
2
Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.
J Exp Pharmacol. 2022 Mar 8;14:97-115. doi: 10.2147/JEP.S346006. eCollection 2022.
3
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Sci Data. 2021 Feb 26;8(1):70. doi: 10.1038/s41597-021-00848-4.
4
Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments.
Front Pharmacol. 2020 Oct 29;11:595888. doi: 10.3389/fphar.2020.595888. eCollection 2020.
5
A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era.
J Clin Med. 2020 Jul 30;9(8):2441. doi: 10.3390/jcm9082441.
6
The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication.
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00056-20.
7
Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
J Lipid Res. 2020 Jul;61(7):972-982. doi: 10.1194/jlr.R120000851. Epub 2020 May 26.
8
Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02372-19.
9
Parechovirus A Pathogenesis and the Enigma of Genotype A-3.
Viruses. 2019 Nov 14;11(11):1062. doi: 10.3390/v11111062.
本文引用的文献
1
Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
Med Mycol. 2017 Jun 1;55(4):375-384. doi: 10.1093/mmy/myw091.
2
Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model.
Sci Rep. 2016 Mar 15;6:23110. doi: 10.1038/srep23110.
3
Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.
Med Mycol. 2016 Feb;54(2):128-37. doi: 10.1093/mmy/myv087. Epub 2015 Oct 18.
4
Human parechovirus infections and child myositis cases associated with genotype 3 in Osaka City, Japan, 2014.
J Med Microbiol. 2015 Nov;64(11):1415-1424. doi: 10.1099/jmm.0.000167. Epub 2015 Jan 11.
5
Enterovirus and Human Parechovirus Surveillance - United States, 2009-2013.
MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):940-3. doi: 10.15585/mmwr.mm6434a3.
6
Replication and Inhibitors of Enteroviruses and Parechoviruses.
Viruses. 2015 Aug 10;7(8):4529-62. doi: 10.3390/v7082832.
7
In Vitro Efficacy of Antiviral Compounds against Enterovirus D68.
Antimicrob Agents Chemother. 2015 Dec;59(12):7779-81. doi: 10.1128/AAC.00766-15. Epub 2015 Sep 14.
8
Parechovirus Genotype 3 Outbreak among Infants, New South Wales, Australia, 2013-2014.
Emerg Infect Dis. 2015 Jul;21(7):1144-52. doi: 10.3201/eid2107.141149.
9
Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A.
Antimicrob Agents Chemother. 2015 May;59(5):2654-65. doi: 10.1128/AAC.05108-14. Epub 2015 Feb 17.
10
Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein.
Cell Rep. 2015 Feb 3;10(4):600-15. doi: 10.1016/j.celrep.2014.12.054. Epub 2015 Jan 29.
Zotero 插件